MedPath

Efficacy of Low-Dose Continuous Infusion of Human Atrial Natriuretic Peptide (hANP) During Lung Resection Surgery

Phase 2
Conditions
ung Resection Surgery
Registration Number
JPRN-UMIN000001524
Lead Sponsor
Toneyama National Hospital
Brief Summary

Continuous infusion of low-dose human atrial natriuretic peptide during lung cancer surgery had a prophylactic effect against postoperative atrial fibrillation after pulmonary resection in patients with preoperative elevation of B-type natriuretic peptide levels.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
whether infusion of hANP during pulmonary resection has an effect on the reduction of postoperative complications (atrial fibrillation)
Secondary Outcome Measures
NameTimeMethod
Postoperative hemodynamics, white blood cell counts, and C-reactive protein levels
© Copyright 2025. All Rights Reserved by MedPath